The team that has been doing this in pharma longer than anyone else — and has the results to prove it
Eularis was founded in 2003 with a single focus: helping pharmaceutical leaders use AI to solve the commercial challenges that matter most. Everything we do flows from that — and has done for over two decades.
The pharmaceutical industry is navigating a period of genuine strategic complexity. Patent cliffs are accelerating. Pipelines are under pressure. Payers are more demanding than ever. And a board-level expectation has formed around AI that most organisations are not yet structurally equipped to meet.
This is not a technology problem. The technology has never been more capable. It is a strategy problem — and it is the problem Eularis was built to solve.
Eularis was founded by Dr. Andrée Bates in 2003 — at a time when applying artificial intelligence to pharmaceutical strategy was considered by most of the industry to be either premature or irrelevant. Two decades later, with AI now at the top of every pharma board agenda, that early commitment has produced something no generalist firm can replicate: a methodology, a body of knowledge, and a team that has been built exclusively around the pharmaceutical AI challenge for longer than the challenge has been widely recognised.
What we have learned across more than two decades and over a thousand pharma AI engagements is this: the firms that achieve lasting results from AI are not those that started with the most sophisticated technology. They are those that started with the most honest and rigorous analysis of the specific decisions that drive their commercial performance — and then designed AI to serve those decisions precisely.
That principle has guided every engagement Eularis has delivered since 2003. It is what distinguishes a strategy that holds up in a board room from one that impresses in a steering committee and quietly disappears.
The breadth of challenges we have solved with AI across the pharmaceutical value chain spans discovery, R&D, manufaturing, supply chain, clinical, regulatory, medical affairs, market access and value pricing. commercial strategy, launch planning, sales and marketing efficiency and effectiveness, portfolio prioritisation, and enterprise productivity. Our case studies are available to review — and we are always willing to discuss specific examples relevant to your organisation’s situation in a direct conversation.
Explore a small sample of our work →
The consistent lesson from over two decades in this space is straightforward: AI initiatives that begin with strategy consistently outperform those that begin with technology selection. Not occasionally. Consistently. The organisations that come to Eularis having already invested significantly in AI tools and seen disappointing returns almost always share the same root cause — the strategic foundation was either absent or insufficiently rigorous to survive contact with the organisation’s real commercial priorities.
That is the gap Eularis closes. And it is why an AI Strategic Blueprint is always where we begin.
The situations that typically bring pharmaceutical leaders to Eularis
- You have significant AI activity underway but genuine uncertainty about what it will actually deliver at board level
- Your organisation faces material exclusivity losses over the next three years and needs AI aligned to revenue protection and replacement — not general efficiency
- Your board or investors are asking for a coherent AI strategy and the current answer is not yet credible enough
- AI pilots have been run, dashboards have been built, but nothing has compounded into enterprise-wide competitive advantage
- You need to deliver measurable short-term results while simultaneously building the AI capability that will define your organisation's position in three to five years
- You have tried to build AI strategy internally or with a generalist consultancy and the output has not survived contact with your organisation's commercial reality
If any of these situations describe where your organisation is right now, we would welcome a direct conversation. Not a sales call — a focused discussion about your specific situation and whether Eularis is the right partner for it.
The firm behind the work
Eularis is a specialist AI strategy and implementation firm working exclusively with pharmaceutical and life sciences organisations. We do not work across sectors. We do not adapt frameworks from other industries. Every methodology we use, every engagement we take on, and every member of our team is focused on a single domain: helping pharma leaders build AI strategies that deliver measurable commercial results in the specific regulatory, scientific, and organisational context of this industry.
Eularis was founded by Dr. Andrée Bates — one of the most experienced figures in pharmaceutical AI strategy in the world and the person who has personally overseen more than a thousand pharma AI engagements across clinical development, medical affairs, market access, and commercial operations over the past two decades.
Dr. Bates began working at the intersection of pharmaceutical strategy and artificial intelligence in 2003 — before AI had entered mainstream pharma conversation, before the industry had developed the frameworks to evaluate it, and before most of the firms now offering AI strategy services existed. That early start is not a biographical detail. It is the source of the depth that makes Eularis’ approach categorically different from firms that have entered this space more recently.
She has lectured on pharmaceutical AI and healthcare innovation at INSEAD, Henley Business School, Fordham University’s Gabelli School of Business, Northwestern University, and Northeastern University — and her published research on AI strategy in pharma is read by executives across the global industry.
The Eularis team is assembled specifically for the biopharmaceutical AI mandate. Our consultants bring a rare combination of qualifications that this work demands: deep pharmaceutical commercial experience at executive level in top-tier global organisations, rigorous AI and data science expertise, and the strategic advisory capability to connect the two in service of board-level decisions.
Across the team, that means practitioners who have held senior roles inside the organisations we now advise — who understand the political dynamics of a global pharma leadership team, the evidence standards of a medical affairs function, and the commercial pressures of a launch in a crowded therapeutic area — not as observers, but as participants. That insider understanding is what allows Eularis to build strategies that survive contact with the organisation rather than stalling at implementation.
Eularis operates globally — with experience delivering AI strategy engagements across North America, South America, Europe, Middle East, Asia Pacific, China and Japan. That geographic breadth matters because the commercial, regulatory, and market access realities that shape AI strategy differ significantly across regions. A blueprint built for the US market is not automatically the right blueprint for a European launch or an Asia Pacific access strategy. Our teams understand those distinctions at a working level — not from frameworks, but from direct experience in those markets.
Organisations that have trusted Eularis with their AI strategy
A representative selection from over two decades of pharma AI engagements across six continents
Three principles that define every Eularis engagement
Exclusively biopharmaceutical and life sciences
Eularis works with one industry. Not because we cannot work across sectors — because we have chosen not to. Twenty years of focus on a single domain produces a depth of commercial, clinical, regulatory, and organisational intelligence that no generalist firm can replicate. Every framework we use was built for pharma. Every lesson we apply was learned in pharma. That focus is deliberate and it is the foundation of everything we deliver.
AI strategy and implementation — not tools, not platforms
Eularis does not sell AI tools or technology platforms. We design the strategic architecture that determines which AI initiatives your organisation should pursue, in which sequence, and why — and then we guide the implementation of those initiatives to ensure they deliver the commercial outcomes they were designed to produce. We are vendor-neutral by principle. Our only interest is your result.
A track record measured in outcomes, not activity
Over 20 years and more than 1,000 pharma AI engagements, we have built a body of evidence that goes beyond client satisfaction. Every drug launch we have supported has become a top brand within its first year. The established brands we have worked with have achieved an average of 29% growth. These are not projections or estimates — they are outcomes from real engagements with real organisations operating in real competitive markets.
in pharma & healthcare AI and FutureTech
cups of coffee consumed each week by Eularis team
Net Promoter Score
projects delivered within budget
What senior leaders in pharma say about working with Eularis
Dr. Bates and Eularis research featured in
What Eularis exists to do
Eularis exists to close the gap between AI’s potential in pharmaceutical strategy and what most pharma organisations are currently able to realise from it. That gap is not technical. The technology is capable. The gap is strategic — and closing it, for pharmaceutical leaders who cannot afford to get this wrong, is the only thing we do.
Our methodology has been refined across more than two decades of pharmaceutical AI engagements — not in a laboratory, not in a think tank, but in the operational reality of real pharmaceutical organisations facing real commercial pressures. It is tested, it is current, and it is specific to the context in which it must perform.
"The pharmaceutical organisations that achieve lasting results from AI are not those that started with the most sophisticated technology. They are those that started with the most honest analysis of the decisions that drive their commercial performance — and then designed AI to serve those decisions precisely." — Dr. Andrée Bates, Founder and CEO, Eularis
If the work described on this page is relevant to where your organisation is right now, the most direct next step is a confidential 45-minute AI Strategy Diagnostic — a focused conversation about your specific situation and an honest read on what needs to happen first.
We work with a select number of organisations each year. If you would like to explore whether Eularis is the right partner for your AI strategy, we would welcome the conversation.
Further resources for pharmaceutical leaders
We got you covered!